Lundbeck still looking for acquisitions despite positive Alzheimer's data
Pharmaceutical firm Lundbeck is still considering acquisition opportunities even though it is heading to the approval application stage for its Alzheimer’s medication.
by christopher due karlsson, translated by catherine brett
Lundbeck is still interested in acquisitions, despite the fact that the firm and its partner Otsuka Pharmaceuticals released positive phase III data for its candidate brexpiprazol on Monday. The target indication is agitation in Alzheimer’s patients, which is often demonstrated through angry outbursts.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Lundbeck lawyer says pharma is fighting over legal talent
For subscribers
